9th Advances Against Aspergillosis and Mucormycosis
Palazzo dei Congressi Lugano, Lugano, Switzerland
27 – 29 February 2020
9th Advances Against Aspergillosis and Mucormycosis
Palazzo dei Congressi Lugano, Lugano, Switzerland
27 – 29 February 2020
9th Advances Against Aspergillosis and Mucormycosis
Palazzo dei Congressi Lugano, Lugano, Switzerland
27 – 29 February 2020
Programme
Go directly to a day’s programme
Thursday | Friday | Saturday
Go directly to a day’s programme
Thursday | Friday | Saturday
Go directly to a day’s programme
Thursday | Friday | Saturday
Thursday | Friday | Saturday
Thursday 27 February 2020 – Day 1 |
|
|---|---|
Meet the Professor |
|
| 08:00 – 08:55 | ECMM and ISHAM joint session: Excellence centres, fellows, guidelines, educational initiatives, working groups and publishing Martin Hönigl, MD & Arunaloke Chakrabarti, MD |
| 08:00 – 08:55 | Kids, difficult asthma and fungus Andrew Bush, MD |
| 09:00 – 09:15 | Introduction and summary of new antifungal drugs David W. Denning, MBBS |
Aspergillus: Modelling the Host and BeyondModerators: David B. Corry, MD, Richard B. Moss, MD & David S. Perlin, PhD |
|
| 09:20 – 09:45 | IL-22 and tryptophan metabolism in antifungal host defense Teresa Zelante, PhD |
| 09:45 – 10:00 | Abstract #49: Uncoupling of cytokine signaling and LC3 associated phagocytosis (LAP) drives the development of invasive aspergillosis in patients with sepsis Tonia Akoumianaki, PhD |
| 10:00 – 10:25 | Respiratory epithelial interaction Kirk M. Druey, MD |
| 10:25 – 10:40 | Abstract #45: “Invasive aspergillosis on-a-chip” – a novel disease model to study Aspergillus fumigatus infection in the human lung Susann Hartung, PhD |
| 10:40 – 11:05 | IL-17 immunity: from Aspergillus to Candida Petra Bacher, PhD |
11:05 – 11:35 | Coffee Break |
Management of the Next DecadeModerators: Arunaloke Chakrabarti, MD, Thomas F. Patterson, MD & Bart-Jan Kullberg, MD PhD |
|
| 11:35 – 12:00 | Genomic predisposition and adaptation ito virulence in aspergillosis Paul Bowyer, PhD |
| 12:00 – 12:15 | Abstract #51: Vaccine-induced immunogenicity and protection in a murine model of invasive pulmonary aspergillosis Emily Rayens |
| 12:15 – 12:30 | Abstract #37: Modulation of TREM1 signalling in macrophages infected with Aspergillus fumigatus Irene González Jiménez, PhD |
| 12:30 – 12:55 | Individualized genetic-based approach for IA prophylaxis Pierre-Yves Bochud, MD |
12.55 – 14.30 | Lunch and Poster Session 1 |
Airways and DiseasesModerators: Teresa Zelante, PhD, Martin Hönigl, MD & Sven Krappmann, PhD |
|
| 14:30 – 14:55 | Regulation of Th2-immunity David B. Corry, MD |
| 14:55 – 15:10 | Abstract #46: Single cell approaches reveal the key dendritic cell subsets that coordinate allergic airway inflammation against the fungal allergen Aspergillus fumigatus Peter Cook, PhD |
| 15:10 – 15:25 | Abstract #74: Interdependency of host and pathogen protein persulfidation governs disease severity in experimental and human aspergilloses Jorge Amich, PhD |
| 15:25 – 15:50 | The structure and immunogenicity of galactomannan Nikolay Nifantiev, PhD |
15:50 – 16:20 | Coffee Break |
Aspergillus: Entering the Host and BeyondModerators: Elaine Bignell, PhD, Yoshitsugu Miyazaki, MD PhD & Gabriele Sass PhD |
|
| 16:20 – 16:45 | Siderophores and fungal pathogenesis Hubertus Haas, PhD |
| 16:45 – 17:00 | Abstract #79: Iron overload decreases macrophage lysosomal acidification, impairing the clearance of Aspergillus fumigatus conidia Mikio Kaji |
| 17:00 – 17:15 | Abstract #73: ROS-dependent and independent host-induced fungal regulated cell death in defence against invasive aspergillosis Neta Shlezinger, PhD |
| 17:15 – 17:40 | Modelling IA – how close are predicted antifungal targets? Thomas Walsh, MD |
17:40 – 18:45 | Welcome Reception |
Go directly to a day’s programme
Thursday | Friday | Saturday
Friday 28 February 2020 – Day 2 |
|
|---|---|
Meet the Professor |
|
| 08:00 – 08:55 | Difficult cases in fungal sinusitis Tarik Mohsena MD FRCPC FACP DTM&H & Arunaloke Chakrabarti, MD |
| 08:00 – 08:55 | How to make a fast and accurate diagnosis – what can the clinician and lab do? Dea Garcia-Hermoso, PhD & Stéphane Ranque, MD PhD |
Emerging AspergilliModerators: Jesús V. Guinea Ortega, PharmD PhD & Stéphane Ranque, MD PhD |
|
| 09:00 – 09:25 | Current epidemiology of invasive fungal infections Nina Khanna, MD |
| 09:25 – 09:40 | Abstract #82: Mucoricin is a mucorales ricin-like toxin critical for mucormycosis pathogenesis Ashraf Ibrahim, PhD |
| 09:40 – 10:05 | Epidemiological surveillance for Aspergillus – is it of any value? Sophie Loeffert-Frémiot, PhD |
| 10:05 – 10:20 | Abstract #92: Virus infection of Aspergillus fumigatus (Af) compromises Af in intermicrobial competition Ioly Kotta-Loizou |
| 10:20 – 10:45 | Aspergillus calidoustus – epidemiology and outcome Frederic Lamoth, MD |
| 10:45 – 11:00 | New support initiatives in aspergillosis and mucormycosis research Dona Love, PhD & Sonia Sanchez, MD |
11:00 – 11:45 | Coffee Break and Poster Viewing |
Pfizer Satellite SymposiumModerator: Robert Krause, MD DTMP |
|
| 11:45 – 13:15 | Introduction and scene setting Robert Krause, MD DTMP |
| 11:55 - 12:05 | Interactive case study part one – setting the scene of a difficult diagnosis Dionysios Neofytos, MD PhD MPH |
| 12:05 - 12:30 | Risk factors for invasive aspergillosis and mucormycosis, and how to pick apart a diagnosis, supported by case studies Carolina Garcia-Vidal, MD PhD |
| 12:30 - 12:55 | Treating invasive mould disease in the case of confounding factors Malgorzata Mikulska, MD PhD |
| 12:55 - 13:05 | Interactive case study part two – treatment approaches to a complex patient with a complicated infection Dionysios Neofytos, MD PhD MPH |
| 13:05 - 13:15 | Discussion, Q&A and close All |
13:15 – 14:00 | Lunch (Sponsored by Pfizer) |
| 14:00 – 15:00 | Poster Viewing |
Go directly to a day’s programme
Thursday | Friday | Saturday
Saturday 29 February 2020 – Day 3 |
|
|---|---|
Meet the Professor |
|
| 08:00 – 08:55 | CLSI/EUCAST: AFST for breakpoints - where we are going? David R. Andes, MD & Jesús V. Guinea Ortega, PharmD, PhD |
| 07:45 – 08:55 | Regulatory endpoints for invasive and chronic pulmonary aspergillosis – what is needed? Oliver Cornely, MD, Thomas F. Patterson, MD, Radu Botgros, MD & Sumathi Nambiar, MD |
Resistance in AspergillusModerators: Nina Khanna, MD, Thomas Walsh, MD & Don Sheppard, MD |
|
| 09:00 – 09:25 | Acquiring azole resistant Aspergilli – where from? Dolores Pinheiro, MD |
| 09:25 – 09:40 | Abstract #59: The negative cofactor 2 complex is a master regulator of drug resistance in Aspergillus fumigatus Takanori Furukawa, PhD |
| 09:40 – 09:55 | Abstract #114: The incidence of pulmonary aspergillosis in patients with cystic fibrosis in Russian Federation Yana Kozlova, MD |
| 09:55 – 10:10 | Abstract #64: CRISPR-Cas9 mutation and characterization of the most overexpressed transcription factor of swollen state of Aspergillus fumigatus Uxue Perez-Cuesta |
| 10:10 – 10:35 | Management of aspergillosis due to azole-resistant Aspergillus fumigatus Bart-Jan Kullberg, MD PhD |
10:35 – 11:05 | Coffee Break |
Molecular MechanismsModerators: Gordon D. Brown, PhD, Hubertus Haas, PhD & Praveen Juvvadi, PhD |
|
| 11:05 – 11:30 | Recognition of DHN-melanin by C–type lectin receptor Gordon D. Brown, PhD |
| 11:30 – 11:45 | Abstract #93: Aspergillus fumigatus KnrA is an intrinsically disordered protein and functions as a potential substrate of calcineurin and protein kinase A in the cell wall integrity pathway Praveen Juvvadi, PhD |
| 11:45 – 12:00 | Abstract #41: Epithelial uptake of Aspergillus fumigatus spores drives efficient fungal clearance in vivo and is aberrant in chronic obstructive pulmonary disease (COPD) patients Margherita Bertuzzi, PhD |
| 12:00 – 12:15 | Abstract #80: Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity Samuel Gonçalves |
| 12:15 – 12:40 | Antimicrobial peptides secreted by Aspergillus fumigatus Sven Krappmann, PhD |
12:40 – 14:20 | Lunch and Poster Session 2 |
Mucormycosis UpdateModerators: Oliver Cornely, MD, Frederic Lamoth, MD & Dea Garcia-Hermoso, PhD |
|
| 14:20 – 14:45 | One world - one guideline: mucormycosis Oliver Cornely, MD |
| 14:45 – 15:10 | Distinguishing invasive mucormycosis from aspergillosis non-invasively Vladimir Havlicek, PhD |
| 15:10 – 15:25 | Abstract #89: Ubiquity, diversity, and functional genomics of Mucoromycota and their Betaproteobacterial endosymbionts Jessie Uehling, PhD |
| 15:25 – 15:40 | Abstract #55: Why are mucormycetes resistant against voriconazole? Michaela Lackner, PhD |
| 15:40 – 16:05 | Mucor species & macrophages Victoriano Garre, PhD |
16:05 – 16:35 | Coffee Break |
Risks for Aspergillus-Related Diseases: Clinical Hot SpotsModerators: Chris Kosmidis, MD PhD & Sophie Loeffert-Frémiot, PhD |
|
| 16:35 – 17:00 | Challenge for chronic pulmonary aspergillosis – a common but formidable disease Yoshitsugu Miyazaki, MD PhD |
| 17:00 – 17:15 | Abstract #117: Prospective evaluation of quality of life and Aspergillus IgG in tuberculosis (TB) patients in Lagos, Nigeria Rita Oladele, PhD |
| 17:15 – 17:40 | Biofilm formation by Aspergillus fumigatus – implications for treatment Don Sheppard, MD |
| 17:40 – 17:55 | Abstract #34: Altered A. fumigatus cell wall integrity by PC945, a novel inhaled azole Darius Armstrong-James, MD PhD |
| 17:55 – 18:20 | The new world of inhaled antifungals & biologics – where might it take us? Richard B. Moss, MD |
18:20 – 18:25 | ClosingWilliam J. Steinbach, MD & David A. Stevens, MD |
18:30 | Snacks and Discussion about AAA 2022 |
